Alpine Immune Sciences (ALPN) Provides Update on ALPN-303

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced the presentation of novel preclinical and clinical data in a poster titled “ALPN-303, an Engineered Dual BAFF/APRIL Antagonist, Potently Inhibits Pathogenic Autoantibodies in Preclinical Models, with Corresponding Pharmacodynamic Activity in Humans,” at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. ALPN-303 is being developed for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.

ALPN-303 is an Fc fusion of an engineered TACI domain that has significantly improved affinity against the B cell cytokines BAFF and APRIL -- particularly the latter, which wild-type TACI-Fc binds inferiorly. Correspondingly superior pharmacokinetics were observed in animals, as well as pharmacological activity in mouse models of immunization and lupus. Preliminary findings in early single dose cohorts of adult healthy volunteers demonstrate dose-dependent reductions in circulating immunoglobulins (IgA, IgG, IgM).

“The preliminary, emerging clinical findings are particularly encouraging,” said Stanford Peng, MD, PhD, Alpine’s President and Head of Research and Development, “because they are highly consistent with our nonclinical data which predict that ALPN-303 may be a more potent yet conveniently-dosed therapeutic. This is of particular importance as we endeavor to surmount challenging target diseases such as lupus and other B-cell related inflammatory diseases.”

A copy of the poster presentation is available on the Scientific Publications page of Alpine’s website.

You May Also Be Interested In

• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Mondi Says It Does Not Intend To Make An Offer For DS Smith